title: Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials.
abstract: Acute lymphoblastic leukemia of T cell lineage (T-ALL) is an aggressive malignant disease which accounts for 15 % of childhood ALL. T(11;14) is the more frequent chromosomal abnormality in childhood T-ALL, but its prognostic value remained controversial. Our aim was to analyze the outcome of childhood T-ALL with t(11;14) to know if the presence of this translocation is associated with a poor prognosis. We conducted a retrospective study from a series of 20 patients with t(11;14), treated in two consecutive trials from the European Organization for Research and Treatment of Cancer Children Leukemia Group over a 19-year period from 1989 to 2008. There were no significant differences between the 2 consecutive groups of patients with t(11;14) regarding the clinical and biological features at diagnosis. Among 19 patients who reached complete remission, 9 patients relapsed. We noticed 7 deaths all relapse- or failure-related. In the 58881 study, a presence of t(11;14) was associated with a poor outcome with an event-free survival at 5 years at 22.2 % versus 65.1 % for the non-t(11;14) T-ALL (p = 0.0004). In the more recent protocol, the outcome of T-ALL with t(11;14) reached that of non-t(11;14) T-ALL with an event-free survival at 5 years at 65.5 versus 74.9 % (p = 0.93). The presence of t(11;14) appeared as a poor prognostic feature in the 58881 trial whereas this abnormality no longer affected the outcome in the 58951 study. This difference is probably explained by the more intensive chemotherapy in the latest trial.
authors.affiliation: Department of Pediatric Hematology-Oncology, CHU, Besançon, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Simon
authors.affiliation: EORTC Headquarters, Brussels, Belgium.
authors.forename: Stefan
authors.initials: S
authors.lastname: Suciu
authors.affiliation: Department of Hemato-Immunology, Robert Debré Hospital, Paris, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Clappier
authors.affiliation: Department of Hemato-Immunology, Robert Debré Hospital, Paris, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Cave
authors.affiliation: Department of Pediatric Hematology-Oncology, University Hospital Lapeyronie, Montpellier, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sirvent
authors.affiliation: Department of Hematology, Children's Hospital, Toulouse, France.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Plat
authors.affiliation: Centre Antoine Lacassagne, Nice, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Thyss
authors.affiliation: Department of Pediatric Hematology-Oncology, CHR, Nantes, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Mechinaud
authors.affiliation: Department of Pediatrics, Escolar San Joao Hospital, Porto, Portugal.
authors.forename: Vitor M
authors.initials: VM
authors.lastname: Costa
authors.affiliation: Department of Hemato-Oncology, HUDE, Brussels, Belgium.
authors.forename: Alina
authors.initials: A
authors.lastname: Ferster
authors.affiliation: Department of Hematology, Hautepierre, Strasbourg, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lutz
authors.affiliation: Department of Pediatric Hematology-Oncology, CHR, Lille, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Mazingue
authors.affiliation: Department of Pediatrics, CHR La Tronche, Grenoble, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Plantaz
authors.affiliation: Department of Pediatric Hematology-Oncology, CHU, Besançon, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Plouvier
authors.affiliation: Institut of Pediatric Hematology-Oncology (IHOP), Lyon, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Bertrand
authors.affiliation: Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium.
authors.forename: Yves
authors.initials: Y
authors.lastname: Benoit
authors.affiliation: Laboratory of Cytogenetics, University Hospital, Toulouse, France.
authors.forename: Nicole
authors.initials: N
authors.lastname: Dastugue
authors.affiliation: Department of Pediatric Hematology-Oncology, CHU, Besançon, France. rohrlich.ps@chu-nice.fr.
authors.forename: Pierre S
authors.initials: PS
authors.lastname: Rohrlich
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D014178:Translocation, Genetic / Q000235:genetics*; D016896:Treatment Outcome
keywords: Pediatric acute lymphoblastic leukemia; Prognosis; T cell; Translocation t(11;14)